Avadel Pharmaceuticals PLC Sponsored ADR Stock

$9.34

5.56% yesterday

Nasdaq, Jun 12, 10:00 pm CET

ISIN

US05337M1045

Symbol

AVDL

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Medical specialties

Overview Dividends Analysts Charts News Strategies

Avadel Pharmaceuticals PLC Sponsored ADR Stock price

$9.34

+1.32 16.46% 5Y

Nasdaq, Closing price Thu, Jun 12 2025

-0.55 5.56%

ISIN

US05337M1045

Symbol

AVDL

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Medical specialties

Key metrics

Market capitalization	$903.54m
Enterprise Value	$837.06m
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
EV/Sales (TTM) EV/Sales	4.30
P/S ratio (TTM) P/S ratio	4.65
P/B ratio (TTM) P/B ratio	12.19
Revenue growth (TTM) Revenue growth	252.65%
Revenue (TTM) Revenue	$194.45m
EBIT (operating result TTM) EBIT	$-19.37m
Free Cash Flow (TTM) Free Cash Flow	$-25.44m
Cash position	$66.48m
EPS (TTM) EPS	$-0.27
P/E forward	62.20
P/S forward	3.47
EV/Sales forward	3.22
Short interest	13.77%

As a Free StocksGuide user, you can view scores for all 6,845 stocks worldwide.

Get Started for Free Today

Avadel Pharmaceuticals PLC Sponsored ADR Stock Analysis

Unlock Scores for Free

??

8 Analysts have issued a Avadel Pharmaceuticals PLC Sponsored ADR forecast:

8x Buy

100%

More details on Analyst Estimates Including Price Targets

8 Analysts have issued a Avadel Pharmaceuticals PLC Sponsored ADR forecast:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Avadel Pharmaceuticals PLC Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	194 194	253% 253% 100%
- Direct Costs	19 19	716% 716% 10%
Gross Profit	175 175	232% 232% 90%
- Selling and Administrative Expenses	178 178	1% 1% 92%
- Research and Development Expense	16 16	32% 32% 8%
EBITDA	-16 -16	89% 89% -8%
- Depreciation and Amortization	2.97 2.97	73% 73% 2%
EBIT (Operating Income) EBIT	-19 -19	87% 87% -10%
Net Profit	-26 -26	83% 83% -14%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Avadel Pharmaceuticals PLC Sponsored ADR Stock News

Neutral

GlobeNewsWire

●

8 days ago

Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

DUBLIN, June 05, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that LUMRYZTM has been granted Orphan Drug Designation (ODD) from the U.S. Food & Drug Administration (FDA) for the treatment of Idiopathic Hypersomnia (IH). Specifically, ODD was granted based on the plausible hyp...

Neutral

GlobeNewsWire

●

15 days ago

Avadel Pharmaceuticals to Present New Data on LUMRYZ™ (sodium oxybate) For Extended-Release Oral Suspension at SLEEP 2025

– 14 abstracts accepted, including four oral presentations – – Interim analysis of real-world REFRESH study demonstrated clinically significant efficacy and improvement of EDS for patients who switched from twice-nightly oxybate to once-at-bedtime LUMRYZ – – Data reflecting the therapeutic results of LUMRYZ treatment in people with narcolepsy across clinical as well as real-world settings will ...

Neutral

GlobeNewsWire

●

15 days ago

Avadel Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

DUBLIN, Ireland, May 29, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 5 at 10:30 a.m. ET. A live webcast of the fireside chat, as well as an archived...

More Avadel Pharmaceuticals PLC Sponsored ADR News

Company Profile

Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. It offers Bloxiverz, Vazculep, and Akovaz. The company was founded on December 1, 2015 and is headquartered in Dublin, Ireland.

Head office	Ireland
CEO	Gregory Divis
Employees	188
Founded	2015
Website	www.avadel.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now